Virus 20structure 20for 20website 2019
Senecalogo 2

Seneca Therapeutics, Inc (STI)

STI is developing Seneca Valley Virus, a cancer immunotherapy. After reactivating the IND STI will start PH 2 studies including orphan and high-need indications

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded February 2018
  • Employees 4
  • Incorporation Type C-corp
  • Website senecatherapeutics.com

Company Summary

Seneca Therapeutics' oncolytic immunotherapeutic (Seneca Valley Virus, SVV) has proven human safety and indications of efficacy in solid cancer clinical trials. STI is preparing to reactivate an existing IND and initiate Phase II clinical trials to demonstrate a 2-3X increased response rate for checkpoint inhibitors in high-need indications. SVV has significant advantages over competitors. STI is targeting a high multiple exit with this data.

Team

  • 2019 06 17
    President and Chief Executive Officer

    Dr. Hallenbeck is the Founder, President and CEO of Seneca. He is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry with expertise in all phases of cancer immuno-therapeutics R&D. As the sole founder of Neotropix, raised $30M in VC, then successfully led SVV (NTX-001) through IND approval, and completed a Phase I/II clinical trial, establishing an excellent safety record & compelling evidence of efficacy.

  • 74122c1c c9ea 4516 b6e5 2287a247816d
    Chief Financial Officer

    Ben is a successful financial and operating management expert in due diligence, profitability analysis and improvement, cash flow management, equity financing, as well as systems selection and implementation. As an advisory board member of Mid-Atlantic Diamond Ventures, he is an invaluable mentor for many high growth investment deals. He performs due diligence for early stage investors & prepares and executes corporate financial transactions.

  • B046c983 4d39 47a7 b512 1daf10e00c5c
    Senior Director of R&D

    Dr, Burroughs is an experienced R&D scientist and leader with almost 20 years in the biopharma industry. He brings a deep understanding across the spectrum of product development and regulatory processes. He has successfully led pre-clinical, clinical and regulatory teams through complete IND-enabling programs, first-in-man Phase I to Phase III pivotal studies, and regulatory interactions resulting in US and international marketing approvals.

  • 8123dd42 57d6 42aa 9116 e5918839ff31
    Vice President of Manufacturing

    Dr. Wechuck is a biochemical engineer with 15 yrs of experience in recombinant protein production, viral vector manufacturing, and biologics testing. He has developed and advanced the proprietary cGMP manufacturing production, purification, and formulation methodologies for Type 1 Diabetes Drug Products and viral vectors for gene therapy products. He has led CMC regulatory elements for several investigational drug applications in the US & Europe.

  • 67b6a23e 1b00 4579 926d 9c4fd323b37c
    Board Director

    Dr. Rakestraw has an extensive and impressive track record managing healthcare capital investments and strategic advisory firms. Dr. Rakestraw has worked with clients and portfolio companies to complete strategic alliance transactions totaling more than $7 billion in realized cash deal values, and has been instrumental in 11 successful Biotech IPOs and the acquisitions of three portfolio companies.

  • E9a80ffd 69e1 4760 8d04 46d739533f41
    Chief Medical Officer

    Dr. Klein is a board certified Allergist and Immunologist, and a board certified Pediatrician. He is an expert in Medical Affairs and Clinical Development and has published numerous scientific papers. He was a professor of Medicine and Pediatrics (Division of Basic and Applied Immunology) at University California, Irvine. Dr. Klein was a founder and CEO of Entera Health Inc. where he led the clinical development and medical affairs programs.